Skip to main content
. 2019 Dec 19;13:4331–4340. doi: 10.2147/DDDT.S225613

Figure 4.

Figure 4

Long-term stability evaluation of RA patients. ESR (A), RF (B), Anti-CCP (C) and CRP (D), before treatment and 1-year posttreatment and 3-year posttreatment with disease-modifying anti-rheumatic drugs (DMARDs) plus umbilical cord mesenchymal stem cells (UC-MSCs). Pre-treatment versus after the first or second treatment, *** represents P < 0.001, ** represents P < 0.01;1-year posttreatment versus 3-year posttreatment, * represents P < 0.05; ns represents no significance (n = 64).